HLA-G and in situ carcinoma: The analysis of disease stage found significantly higher relative HLA-G mRNA expression in patients with pT2 and pT3 as compared to patients with pTa/CIS and pT1 (2.101 ± 2.008 vs. 1.086 ± 1.786, p = 0.0436, Table 5).